CN114225090A - Chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and preparation method thereof - Google Patents
Chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and preparation method thereof Download PDFInfo
- Publication number
- CN114225090A CN114225090A CN202111650654.5A CN202111650654A CN114225090A CN 114225090 A CN114225090 A CN 114225090A CN 202111650654 A CN202111650654 A CN 202111650654A CN 114225090 A CN114225090 A CN 114225090A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- nanofiber
- solution
- wound dressing
- aminolevulinic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 51
- 239000002121 nanofiber Substances 0.000 title claims abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 21
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 21
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical group NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000001523 electrospinning Methods 0.000 claims abstract description 16
- 229960001149 dopamine hydrochloride Drugs 0.000 claims abstract description 14
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 14
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960002749 aminolevulinic acid Drugs 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000835 fiber Substances 0.000 claims abstract description 4
- 230000001070 adhesive effect Effects 0.000 claims abstract description 3
- 125000003158 alcohol group Chemical group 0.000 claims abstract description 3
- 229940045110 chitosan Drugs 0.000 claims abstract description 3
- 239000011258 core-shell material Substances 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 7
- -1 5-aminolevulinic acid-dopamine Chemical compound 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 230000000249 desinfective effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 20
- 206010052428 Wound Diseases 0.000 abstract description 19
- 239000000463 material Substances 0.000 abstract description 6
- 230000002439 hemostatic effect Effects 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 208000031737 Tissue Adhesions Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H1/43825—Composite fibres
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Abstract
The invention provides a chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and a preparation method thereof, wherein the chitosan-based nanofiber wound dressing is core-shell type nanofibers, and a nanofiber membrane with the fiber diameter of 100nm-20 mu m is obtained by electrospinning in a coaxial electrostatic spinning mode. Wherein the polyvinyl alcohol forms the shell of the nanofiber and the chitosan, dopamine hydrochloride and 5-aminolevulinic acid form the core of the nanofiber. Experiments prove that the chitosan-based nanofiber membrane modified by dopamine hydrochloride and 5-aminolevulinic acid has good hemostatic performance and biocompatibility. By adding dopamine hydrochloride and 5-aminolevulinic acid into the chitosan solution, the good water absorption and fibroblasticity of polyvinyl alcohol in the original material and the hemostatic property of chitosan are maintained, and the adhesive property and antibacterial property to biological tissues such as skin, organs and the like are improved, and the wound healing is promoted.
Description
Technical Field
The invention relates to a chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and a preparation method thereof, belonging to the field of biomedical materials.
Background
Traumatic hemorrhage is one of the most common injuries in battlefields and various accident sites, and uncontrolled hemorrhage is the leading cause of death of wounded personnel in the scene. In fact, the casualties resulting from bleeding are mostly avoidable. The bandage widely used at present is combat gauze, but bacterial infection of wounds is also a great factor causing death of wounded persons. Meanwhile, the diabetic patients have serious complications, the wound surface is closed very slowly, the infection rate is high, amputation or limb breakage is caused, the medical cost is high, and the life quality of the patients is poor. In order to improve the survival rate of patients, the wound dressing needs to be upgraded and improved, and the chitosan-based wound dressing is researched more.
Chitosan is a natural high molecular polymer and belongs to aminopolysaccharide. Is the only cationically charged basic polysaccharide found to date. The chitosan has the characteristics of no irritation, no toxicity, antifungal property, good biocompatibility, good oxygen permeability and the like, and can be used for treating various wound surfaces. However, chitosan has poor hydrophilicity, solubility and tissue adhesion, and its antibacterial property against drug-resistant bacteria chitosan is not satisfactory.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide the chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and the preparation method thereof. By adopting the method, the excellent hemostatic property of the chitosan is utilized, and the hydrophilicity, the fiber forming property and the mechanical property of the polyvinyl alcohol reinforced material are added. The catechol group in the dopamine interacts with amino or sulfur groups in tissues to show good adhesion with the tissues, so that the dopamine hydrochloride is added into the chitosan solution to enhance the tissue adhesion of the wound dressing.
The 5-aminolevulinic acid is applied to a wound, can be converted into protoporphyrin PpIX in skin tissues, generates active oxygen through laser irradiation to kill bacteria, and meanwhile, the 5-aminolevulinic acid has a good treatment effect on skin inflammation. Therefore, the 5-aminolevulinic acid is added to enhance the antibacterial property of the wound dressing and accelerate the healing of the wound, the membrane structure obtained by the electrostatic spinning mode has better mechanical strength, high internal porosity, large specific surface area and good form adaptability, can be used for irregular form wound surfaces, and has the advantages of green and pollution-free manufacturing process and low price.
A preparation method of chitosan-based nanofiber wound dressing with adhesion and antibacterial performance comprises the following steps:
(1) dissolving chitosan into an acetic acid solution, completely dissolving to obtain a chitosan solution, then adding dopamine hydrochloride and 5-aminolevulinic acid, and uniformly stirring to obtain a 5-aminolevulinic acid-dopamine hydrochloride-chitosan solution;
(2) preparing a polyvinyl alcohol solution by using deionized water;
(3) building an electrostatic spinning device, taking the 5-aminolevulinic acid-dopamine hydrochloride-chitosan solution obtained in the step (1) as a core solution, taking the polyvinyl alcohol solution obtained in the step (2) as a shell solution, respectively filling the two solutions into corresponding syringes, and performing electrospinning in a coaxial electrospinning mode to obtain a nanofiber membrane;
(4) and (3) drying the obtained electrostatic spinning nanofiber membrane for more than 12 hours in vacuum, and disinfecting.
Further, the volume concentration of the acetic acid in the step (1) is 1% V/V.
Further, the concentration of the chitosan in the chitosan solution in the step (1) is 1-3% M/V.
Further, the mass ratio of the chitosan, the dopamine hydrochloride and the 5-aminolevulinic acid added in the step (1) is 80:6: 15.
Further, the concentration of the polyvinyl alcohol in the step (2) is 10% M/V.
Further, the voltage for carrying out coaxial electrospinning by using an electrostatic spinning device in the step (3) is 10-15 kV; the distance between the needle of the electrostatic spinning device and the collecting device is 10-20 cm.
Further, the collecting device in the step (3) is a rotary drum.
Further, the syringe advancing speed in the step (3) is 0.2-0.35 ml/h.
According to the chitosan-based nanofiber wound dressing prepared by the method, the chitosan-based nanofiber wound dressing is core-shell type nanofibers, and a nanofiber membrane is obtained by electrospinning in a coaxial electrostatic spinning mode, wherein polyvinyl alcohol forms a shell of the nanofibers, and chitosan, dopamine hydrochloride and 5-aminolevulinic acid form a core of the nanofibers.
Further, the diameter of the fiber of the nanofiber membrane is 100nm-20 μm.
Advantageous effects
(1) The nanofiber membrane provided by the invention takes chitosan as a main body, dopamine hydrochloride is added, the dopamine can enhance the tissue adhesion of the material, and both the dopamine and the material have good biocompatibility.
(2) The nanofiber membrane provided by the invention takes chitosan as a main body, and 5-aminolevulinic acid is added to enhance the antibacterial property of the wound dressing and accelerate wound healing.
(3) According to the invention, 5-aminolevulinic acid is added into the electrospinning nuclear solution, and the sustained release can be realized by adopting a coaxial electrospinning mode, so that the effect of controlling the drug release is achieved.
(4) By adding dopamine hydrochloride and 5-aminolevulinic acid into the chitosan solution, the good water absorption and fibroblasticity of polyvinyl alcohol in the original material and the hemostatic property of chitosan are maintained, and the adhesive property and antibacterial property to biological tissues such as skin, organs and the like are improved, and the wound healing is promoted.
Drawings
FIG. 1 is an infrared spectrum of a sample of example 2 of the present invention and a sample of example 3.
FIG. 2 is a SEM image of a sample of example 2 of the present invention.
FIG. 3 is a bar graph of the adhesion strength of the experimental sample of the pigskin adhesion of the sample of example 1, example 2 and example 3 of the present invention.
FIG. 4 is a bar graph of bacterial survival for the samples of example 1, example 2, example 3, and example 3 plus laser according to the present invention.
FIG. 5 is a histogram showing the blood coagulation times of the samples of example 1, example 2 and example 3 of the present invention.
FIG. 6 optical photograph of mouse liver adhesion of example 3 sample of the present invention.
Detailed Description
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are illustrative only for the purpose of explaining the present invention, and are not to be construed as limiting the present invention.
The invention adopts the following technical scheme for solving the technical problems:
example 1:
1 g of polyvinyl alcohol was dissolved in 10ml of deionized water to obtain a polyvinyl alcohol solution having a concentration of 10% M/V.
And (3) carrying out electrostatic spinning on the polyvinyl alcohol solution, wherein the electrostatic spinning condition is high pressure of 15kv, the receiving distance is 10cm, the propelling speed of an injector is 0.3ml/h, the rotating speed of a roller collector is 500rpm, after the electrospinning is finished, collecting the obtained sample, carrying out vacuum drying for more than 12h, and storing the sample.
Example 2:
1 g of polyvinyl alcohol was dissolved in 10ml of deionized water to obtain a polyvinyl alcohol solution having a concentration of 10% M/V. 0.3 g of chitosan was dissolved in 1% V/V acetic acid solution by volume to give a 3% M/V chitosan solution.
And (3) taking the polyvinyl alcohol solution as a shell solution and the chitosan solution as a core solution, and injecting the solutions into corresponding injectors. And (3) carrying out coaxial electrostatic spinning under the conditions of high pressure of 15kv, receiving distance of 10cm, injector propulsion speed of 0.3ml/h and rotating speed of 500rpm of a roller collector, collecting the obtained sample after the electrospinning is finished, carrying out vacuum drying for more than 12h, and storing the sample.
Example 3:
1 g of polyvinyl alcohol was dissolved in 10ml of deionized water to obtain a polyvinyl alcohol solution having a concentration of 10% M/V. 0.3 g of chitosan is dissolved in 1% V/V acetic acid solution by volume concentration to obtain 3% M/V chitosan solution, 0.02 g of dopamine hydrochloride and 0.05 g of 5-aminolevulinic acid are dissolved in the chitosan solution to obtain 5-aminolevulinic acid-dopamine hydrochloride-chitosan solution. And (3) taking the polyvinyl alcohol solution as a shell solution and the chitosan-dopamine hydrochloride solution as a core solution, and injecting the solutions into corresponding injectors. And (3) carrying out coaxial electrostatic spinning under the conditions of high pressure of 15kv, receiving distance of 10cm, injector propulsion speed of 0.3ml/h and rotating speed of 500rpm of a roller collector, collecting the obtained sample after the electrospinning is finished, carrying out vacuum drying for more than 12h, and storing the sample.
Claims (10)
1. A preparation method of chitosan-based nanofiber wound dressing with adhesion and antibacterial performance is characterized by comprising the following steps:
(1) dissolving chitosan into an acetic acid solution, completely dissolving to obtain a chitosan solution, then adding dopamine hydrochloride and 5-aminolevulinic acid, and uniformly stirring to obtain a 5-aminolevulinic acid-dopamine hydrochloride-chitosan solution;
(2) preparing a polyvinyl alcohol solution by using deionized water;
(3) building an electrostatic spinning device, taking the 5-aminolevulinic acid-dopamine hydrochloride-chitosan solution obtained in the step (1) as a core solution, taking the polyvinyl alcohol solution obtained in the step (2) as a shell solution, respectively filling the two solutions into corresponding syringes, and performing electrospinning in a coaxial electrospinning mode to obtain a nanofiber membrane;
(4) and (3) drying the obtained electrostatic spinning nanofiber membrane for more than 12 hours in vacuum, and disinfecting.
2. The method according to claim 1, wherein the volume concentration of acetic acid in the step (1) is 1% V/V.
3. The method according to claim 1, wherein the concentration of chitosan in the chitosan solution in the step (1) is 1-3% M/V.
4. The preparation method according to claim 1, wherein the mass ratio of the chitosan, the dopamine hydrochloride and the 5-aminolevulinic acid added in the step (1) is 80:6: 15.
5. The method according to claim 1, wherein the concentration of the polyvinyl alcohol in the step (2) is 10% M/V.
6. The preparation method according to claim 1, wherein the voltage for the coaxial electrospinning in the step (3) by using the electrospinning device is 10-15 kV; the distance between the needle of the electrostatic spinning device and the collecting device is 10-20 cm.
7. The method according to claim 6, wherein the collecting device in the step (3) is a rotating drum.
8. The method according to claim 1, wherein the syringe advance speed in the step (3) is 0.2 to 0.35 ml/h.
9. The chitosan-based nanofiber wound dressing prepared according to any one of claims 1 to 8, wherein the chitosan-based nanofiber wound dressing is a core-shell type nanofiber, and a nanofiber membrane is obtained by electrospinning in a coaxial electrospinning manner, wherein polyvinyl alcohol forms a shell of the nanofiber, and chitosan, dopamine hydrochloride and 5-aminolevulinic acid form a core of the nanofiber.
10. A chitosan-based nanofiber wound dressing with adhesive and antibacterial properties, according to claim 9, characterized in that the nanofiber membrane has a fiber diameter of 100nm-20 μ ι η.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111650654.5A CN114225090A (en) | 2021-12-30 | 2021-12-30 | Chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111650654.5A CN114225090A (en) | 2021-12-30 | 2021-12-30 | Chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114225090A true CN114225090A (en) | 2022-03-25 |
Family
ID=80744647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111650654.5A Pending CN114225090A (en) | 2021-12-30 | 2021-12-30 | Chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114225090A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114849052A (en) * | 2022-04-24 | 2022-08-05 | 浙江理工大学 | Microneedle patch for repairing diabetic skin wounds and preparation method thereof |
| CN115262223A (en) * | 2022-08-23 | 2022-11-01 | 青岛大学 | Polyester/chitosan gel composite fiber membrane and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103611182A (en) * | 2013-12-10 | 2014-03-05 | 东华大学 | Preparation method of core-shell structure superfine fiber carrier material for medical dressing |
| CN107469140A (en) * | 2017-08-14 | 2017-12-15 | 高鼎精细化工(昆山)有限公司 | A kind of photodynamics antiseptic dressing for having antibacterial functions, preparation method and application |
-
2021
- 2021-12-30 CN CN202111650654.5A patent/CN114225090A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103611182A (en) * | 2013-12-10 | 2014-03-05 | 东华大学 | Preparation method of core-shell structure superfine fiber carrier material for medical dressing |
| CN107469140A (en) * | 2017-08-14 | 2017-12-15 | 高鼎精细化工(昆山)有限公司 | A kind of photodynamics antiseptic dressing for having antibacterial functions, preparation method and application |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114849052A (en) * | 2022-04-24 | 2022-08-05 | 浙江理工大学 | Microneedle patch for repairing diabetic skin wounds and preparation method thereof |
| CN115262223A (en) * | 2022-08-23 | 2022-11-01 | 青岛大学 | Polyester/chitosan gel composite fiber membrane and preparation method thereof |
| CN115262223B (en) * | 2022-08-23 | 2023-12-26 | 青岛大学 | Polyester/chitosan gel composite fiber film and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ambekar et al. | Advancements in nanofibers for wound dressing: A review | |
| TWI445555B (en) | Dressing comprising active components of centella asiatica and use of the same | |
| CN107802878B (en) | Modified gelatin/potassium-sodium niobate composite electroactive antibacterial biological dressing and preparation and application thereof | |
| CN110354295B (en) | Photo-thermal conversion material and preparation method thereof | |
| CN114225090A (en) | Chitosan-based nanofiber wound dressing with adhesion and antibacterial performance and preparation method thereof | |
| CN103933602A (en) | Preparation method of chitosan-based drug-loading composite antibacterial superfine fiber membrane | |
| CN111945301B (en) | Membrane for releasing nitric oxide based on near-infrared response, preparation method and application | |
| CN107823692B (en) | Wound dressing composite nanofiber membrane and preparation method thereof | |
| CN103480027B (en) | Preparation method of bacterial cellulose composite chitosan fiber moist dressing | |
| JP2008163520A (en) | Chitosan/sericin composite nanofiber and utilization of the same to artificial skin | |
| Zhang et al. | Fabrication of green poly (vinyl alcohol) nanofibers using natural deep eutectic solvent for fast-dissolving drug delivery | |
| CN103480042B (en) | Artificial dura mater spinalis, and preparation method and use method thereof | |
| CN103505758A (en) | Chitosan-nanofiber hemostatic material and preparation method thereof | |
| CN115154642B (en) | Bionic asymmetric sponge dressing and preparation method thereof | |
| CN111617303A (en) | Preparation method of high-strength nanofiber membrane wound dressing | |
| Liu et al. | Research progress on the use of micro/nano carbon materials for antibacterial dressings | |
| CN112587717A (en) | Metal cation crosslinked alginate/bacterial cellulose composite hydrogel antibacterial dressing | |
| CN112807475A (en) | High-air-permeability degradable drug-loaded skin wound dressing and preparation method thereof | |
| CN115487337A (en) | Dressing patch for skin repair and preparation method thereof | |
| CN114000262A (en) | Drug-loaded polydopamine-coated nanofiber dressing and preparation method thereof | |
| CN105727358B (en) | Drug-loaded biological high-molecular composite nanometer tunica fibrosa and preparation method thereof | |
| CN113005633A (en) | Antibacterial nanofiber membrane and preparation method and application thereof | |
| CN109529090A (en) | A kind of polyvinyl alcohol spinning nanofiber film dressing containing various metals ion and preparation method | |
| CN108286126A (en) | A kind of preparation method of quick-acting haemostatic powder composite cellulosic membrane | |
| CN113244437A (en) | Preparation method and application of bionic multifunctional composite sponge dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220325 |